Sign up to all DiabetesontheNet journals
Journals
Sign up to all DiabetesontheNet journals
By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.
Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.
We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.
Diabetes &
Primary Care
Issue:
Vol:16 | No:04
Introducing a new consensus document on blood glucose monitoring
We are all aware that the NHS will face some major challenges in the near future and a recent report has outlined some of these challenges (Ham, 2014):
We also know that the incidence of diabetes is growing; figures released in February this year show that there are 3.2 million people with diabetes in the UK (Diabetes UK, 2014). A high proportion of those people will require blood glucose monitoring to help assess the effectiveness of their prescribed treatment. Depending on which side of the fence you sit on, this will determine how valuable you perceive blood glucose monitoring to be. For example, if you are a member of the local Medicines Management Team, you may see blood glucose monitoring as an expensive waste of money for most people with type 2 diabetes; however, if you are a person with type 2 diabetes who is engaged with your diabetes care and uses the results from blood glucose monitoring to adjust dietary intake and physical activity to enable you to achieve target blood glucose levels, you will probably agree that this will save the NHS money through a reduction in costly long-term complications. It is known that the largest portion of the NHS diabetes budget is spent on treating long-term complications, not on day-to-day medication (Diabetes UK, 2012).
The debate about the value of blood glucose monitoring has continued for a long time without any recent evidence or information to guide this debate. Until now, the last document to offer any support to the argument was the last consensus document by Owens et al (2004).
TREND-UK recognised this gap and set about producing a consensus document on blood glucose monitoring. This document lays out both the positive and negative aspects of using blood glucose monitoring as a tool and is designed to assist both healthcare professionals and people with diabetes in having a balanced discussion about the options available and the true value of monitoring blood glucose.
A number of healthcare professionals and people with diabetes contributed to the development of this document to ensure its impartiality and credibility. TREND-UK hope this document will support both healthcare professionals and people with diabetes to appreciate the appropriate use and value of blood glucose monitoring, particularly as a tool to assist the implementation of individual care plans and achieve better health outcomes.
You can find a copy of this TREND-UK consensus document on blood glucose monitoring here.
We are all aware that the NHS will face some major challenges in the near future and a recent report has outlined some of these challenges (Ham, 2014):
We also know that the incidence of diabetes is growing; figures released in February this year show that there are 3.2 million people with diabetes in the UK (Diabetes UK, 2014). A high proportion of those people will require blood glucose monitoring to help assess the effectiveness of their prescribed treatment. Depending on which side of the fence you sit on, this will determine how valuable you perceive blood glucose monitoring to be. For example, if you are a member of the local Medicines Management Team, you may see blood glucose monitoring as an expensive waste of money for most people with type 2 diabetes; however, if you are a person with type 2 diabetes who is engaged with your diabetes care and uses the results from blood glucose monitoring to adjust dietary intake and physical activity to enable you to achieve target blood glucose levels, you will probably agree that this will save the NHS money through a reduction in costly long-term complications. It is known that the largest portion of the NHS diabetes budget is spent on treating long-term complications, not on day-to-day medication (Diabetes UK, 2012).
The debate about the value of blood glucose monitoring has continued for a long time without any recent evidence or information to guide this debate. Until now, the last document to offer any support to the argument was the last consensus document by Owens et al (2004).
TREND-UK recognised this gap and set about producing a consensus document on blood glucose monitoring. This document lays out both the positive and negative aspects of using blood glucose monitoring as a tool and is designed to assist both healthcare professionals and people with diabetes in having a balanced discussion about the options available and the true value of monitoring blood glucose.
A number of healthcare professionals and people with diabetes contributed to the development of this document to ensure its impartiality and credibility. TREND-UK hope this document will support both healthcare professionals and people with diabetes to appreciate the appropriate use and value of blood glucose monitoring, particularly as a tool to assist the implementation of individual care plans and achieve better health outcomes.
You can find a copy of this TREND-UK consensus document on blood glucose monitoring here.
Diabetes UK (2012) NHS spending on diabetes ‘to reach £16.9 billion by 2035’. Diabetes UK. London. Available at:http://bit.ly/1fw5Hfc (accessed 02.07.14)
Diabetes UK (2014) Number of people diagnosed with diabetes reaches 3.2 million. Diabetes UK, London. Available at:http://bit.ly/1fEIDJc (accessed 02.07.14)
Ham C (2014) Reforming the NHS from within: Beyond hierarchy, inspection and markets. The King’s Fund, London. Available at:http://bit.ly/1kRpgPV (accessed 02.07.14)
Owens D, Barnett A, Pickup J et al (2004) Blood glucose self-monitoring in type 1 and type 2 diabetes: reaching a multidisciplinary consensus. Diabetes & Primary Care 6: 8–16
Prescribing pearls: A guide to pioglitazone
Diabetes Distilled: Diabetes remission in the real world
Hypertension case finding and treatment to target as part of the NHS diabetes eye screening programme
Q&A: Lipid management – Part 3: Triglycerides and use of non-statin drugs
Diabetes Distilled: Impact of metformin timing on glucose and GLP-1 response
Diabetes Distilled: Diabetes-related foot ulcers – detailed advice for primary care
Conference over coffee: Diabetes and obesity within multiple long-term conditions
Understanding pioglitazone: The essential information in one place.
3 Sep 2024
Early data from the NHS Type 2 Diabetes Path to Remission programme show it is effective in achieving remission at scale outside of clinical trials.
3 Sep 2024
A pathway offering opportunistic blood pressure checks during eye screening to support hypertension case finding and follow-up.
29 Aug 2024
Claire Davies answers questions on triglycerides and non-statin drugs.
22 Aug 2024